Ariad Pharmaceuticals Inc fka ARIA

[iandy]

While nothing is a lock I agree that Pona alone should get up into the high teens.

Aria will probably receive initial approval in patients failing the second-generation drugs.If that is the take away from ASH I can see us trading in the $13-15 range.
The company would like to maximize differentiation from the other drugs and encourage physicians to use ponatinib earlier in patients with T315I disease. They will most likely need an approved T315I diagnostic test to market differentiation from other drugs and encourage physicians to use ponatinib earlier in patients with T315I disease.If the diagnostic test for the T315I mutation is ready for filing at approximately the same time as the ponatinib application is filed that should be worth a couple of bucks.

In MHO the biggest risks shorting the stock are the possibility of the company being acquired and the early 113 results next year.
The biggest risks to a long are the instability of the market, the expected dilution, and the conjectured untrustworthiness of the CEO.